Excessive fructose intake causes 1,25-(OH)(2)D(3)-dependent inhibition of intestinal and renal calcium transport in growing rats

Am J Physiol Endocrinol Metab. 2013 Jun 15;304(12):E1303-13. doi: 10.1152/ajpendo.00582.2012. Epub 2013 Apr 9.

Abstract

We recently discovered that chronic high fructose intake by lactating rats prevented adaptive increases in rates of active intestinal Ca(2+) transport and in levels of 1,25-(OH)2D3, the active form of vitamin D. Since sufficient Ca(2+) absorption is essential for skeletal growth, our discovery may explain findings that excessive consumption of sweeteners compromises bone integrity in children. We tested the hypothesis that 1,25-(OH)2D3 mediates the inhibitory effect of excessive fructose intake on active Ca(2+) transport. First, compared with those fed glucose or starch, growing rats fed fructose for 4 wk had a marked reduction in intestinal Ca(2+) transport rate as well as in expression of intestinal and renal Ca(2+) transporters that was tightly associated with decreases in circulating levels of 1,25-(OH)2D3, bone length, and total bone ash weight but not with serum parathyroid hormone (PTH). Dietary fructose increased the expression of 24-hydroxylase (CYP24A1) and decreased that of 1α-hydroxylase (CYP27B1), suggesting that fructose might enhance the renal catabolism and impair the synthesis, respectively, of 1,25-(OH)2D3. Serum FGF23, which is secreted by osteocytes and inhibits CYP27B1 expression, was upregulated, suggesting a potential role of bone in mediating the fructose effects on 1,25-(OH)2D3 synthesis. Second, 1,25-(OH)2D3 treatment rescued the fructose effect and normalized intestinal and renal Ca(2+) transporter expression. The mechanism underlying the deleterious effect of excessive fructose intake on intestinal and renal Ca(2+) transporters is a reduction in serum levels of 1,25-(OH)2D3. This finding is significant because of the large amounts of fructose now consumed by Americans increasingly vulnerable to Ca(2+) and vitamin D deficiency.

Keywords: FGF23; bone; growth; intestine; kidney; parathyroid hormone; vitamin D.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • 25-Hydroxyvitamin D3 1-alpha-Hydroxylase / genetics
  • Age Factors
  • Animals
  • Bone Development / drug effects
  • Bone Development / physiology
  • Bone and Bones / metabolism
  • Calcitriol / metabolism*
  • Calcium / metabolism*
  • Fructose / adverse effects*
  • Gene Expression Regulation, Enzymologic / drug effects
  • Glucaric Acid / pharmacology
  • Intestinal Absorption / drug effects*
  • Intestinal Absorption / physiology*
  • Intestinal Mucosa / metabolism
  • Intestines / growth & development
  • Kidney / growth & development
  • Kidney / metabolism
  • Male
  • Random Allocation
  • Rats
  • Rats, Sprague-Dawley
  • Steroid Hydroxylases / genetics
  • Vitamin D Deficiency / metabolism
  • Vitamin D3 24-Hydroxylase

Substances

  • Fructose
  • Steroid Hydroxylases
  • Cyp24a1 protein, rat
  • Vitamin D3 24-Hydroxylase
  • 25-Hydroxyvitamin D3 1-alpha-Hydroxylase
  • Calcitriol
  • Glucaric Acid
  • Calcium